Key facts
- AstraZeneca suggests Hong Kong needs a new healthcare financial model to attract global biotech investment.
- The pharmaceutical giant invested over HK$200 million (US$25.5 million) in Hong Kong in the last three years.
- Hong Kong remains a key research and development hub for AstraZeneca.
Hong Kong can attract more global biotech investments if the city builds up a new healthcare financial model, according to AstraZeneca. While global drug makers have been doubling down on investments in mainland China in recent years, AstraZeneca brought over 60 clinical trials to the city and invested over HK$200 million (US$25.5 million) over the past three years. Hong Kong was still a key research and development hub for the firm.